Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 1

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 3(2)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06712771Phase 3Active Not Recruiting

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Role: lead

NCT06322628Phase 2Active Not Recruiting

A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients

Role: lead

NCT05902598Phase 3Completed

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

Role: lead

NCT05851066Phase 1Completed

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

Role: lead

NCT05757596Phase 1Completed

Study of VSA001 Injection in Chinese Healthy Adult Volunteers

Role: lead

All 5 trials loaded